{"analyses":[{"ciLowerLimit":"-0.03","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"28.55","groupDescription":"1-Year TC3 or IC3-WT Population","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"14.26"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.00","upperLimit":"61.27","value":"50.64"},{"groupId":"OG001","lowerLimit":"55.36","upperLimit":"74.43","value":"64.90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"},{"description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG001","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","timeFrame":"Baseline to 1 year or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)","title":"Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}